1. Home
  2. AUPH vs MTAL Comparison

AUPH vs MTAL Comparison

Compare AUPH & MTAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • MTAL
  • Stock Information
  • Founded
  • AUPH 1993
  • MTAL 2021
  • Country
  • AUPH Canada
  • MTAL Jersey
  • Employees
  • AUPH N/A
  • MTAL N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • MTAL Blank Checks
  • Sector
  • AUPH Health Care
  • MTAL Finance
  • Exchange
  • AUPH Nasdaq
  • MTAL Nasdaq
  • Market Cap
  • AUPH 1.4B
  • MTAL 1.0B
  • IPO Year
  • AUPH 1999
  • MTAL 2021
  • Fundamental
  • Price
  • AUPH $12.68
  • MTAL $12.21
  • Analyst Decision
  • AUPH Strong Buy
  • MTAL Hold
  • Analyst Count
  • AUPH 3
  • MTAL 4
  • Target Price
  • AUPH $12.00
  • MTAL $12.08
  • AVG Volume (30 Days)
  • AUPH 1.6M
  • MTAL 1.2M
  • Earning Date
  • AUPH 11-06-2025
  • MTAL 11-09-2025
  • Dividend Yield
  • AUPH N/A
  • MTAL N/A
  • EPS Growth
  • AUPH N/A
  • MTAL N/A
  • EPS
  • AUPH 0.42
  • MTAL N/A
  • Revenue
  • AUPH $260,111,000.00
  • MTAL $321,804,000.00
  • Revenue This Year
  • AUPH $16.92
  • MTAL $17.39
  • Revenue Next Year
  • AUPH $14.43
  • MTAL $24.69
  • P/E Ratio
  • AUPH $30.61
  • MTAL N/A
  • Revenue Growth
  • AUPH 25.59
  • MTAL N/A
  • 52 Week Low
  • AUPH $6.43
  • MTAL $7.69
  • 52 Week High
  • AUPH $12.90
  • MTAL $14.31
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 68.30
  • MTAL 65.29
  • Support Level
  • AUPH $12.06
  • MTAL $12.12
  • Resistance Level
  • AUPH $12.90
  • MTAL $12.22
  • Average True Range (ATR)
  • AUPH 0.36
  • MTAL 0.03
  • MACD
  • AUPH -0.03
  • MTAL 0.00
  • Stochastic Oscillator
  • AUPH 91.73
  • MTAL 94.74

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About MTAL Metals Acquisition Limited

MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.

Share on Social Networks: